Valuation Laboratorios Farmaceuticos Rovi, S.A. OTC Markets
Stocks
LABF.F
ES0157261019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.86 USD | -27.31% |
|
-.--% | - |
| 05-13 | Spanish stocks - Factors to watch on May 13 | RE |
| 05-09 | Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026 |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 3,008 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -7.4% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 2,985 | 2,917 | 2,806 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -8.77% | -2.28% | -3.8% |
| P/E Ratio | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 22.5x | 16.5x | 13.9x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 3.98x | 3.41x | 2.92x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | -4.59x | 0.5x | 0.7x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 3.89x | 3.29x | 3.05x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 3.86x | 3.19x | 2.84x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 14.6x | 10.8x | 8.86x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 17.4x | 12.4x | 10x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 31.6x | 23.4x | 17x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 3.17% | 4.27% | 5.88% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.9732 | 1.17 | 1.359 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.66% | 1.99% | 2.31% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 2.615 | 3.566 | 4.238 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 37.2% | 32.8% | 32.1% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 774 | 913.1 | 986.9 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 204.2 | 270.3 | 316.7 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 171.6 | 235.6 | 280.5 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 133 | 182.6 | 217 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -22.53 | -90.52 | -201.4 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 58.80 | 58.80 | 58.80 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,149 | - | - |
| Announcement Date | 2/23/22 A | 2/21/23 A | 2/27/24 A | 2/25/25 A | 2/24/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.97x | 12.34x | 25.42x | 0.59% | 1,035B | |
| 25.47x | 5.87x | 15.96x | 2.24% | 574B | |
| 27.52x | 6.71x | 13.7x | 3.05% | 397B | |
| 17.45x | 4.31x | 10.59x | 3.08% | 324B | |
| 22.84x | 4.75x | 13.5x | 1.84% | 281B | |
| 21.11x | 5.44x | 13.22x | 2.98% | 278B | |
| 12.49x | 4.69x | 9.58x | 4.02% | 193B | |
| 23.02x | 6.15x | 10.74x | 2.85% | 191B | |
| -45.04x | 5.44x | 30.73x | 2.58% | 156B | |
| Average | 15.43x | 6.19x | 15.94x | 2.58% | 381.1B | |
| Weighted average by Cap. | 22.87x | 7.58x | 17.64x | 2.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- LABF.F Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
